BioAge Labs (BIOA) EBITDA Margin (2025 - 2026)
BioAge Labs' (BIOA) quarterly EBITDA Margin came in at 810.17% in Q1 2026, up 7949.0% year-on-year from 10.07% in Q1 2025, and up 3.87% quarter-over-quarter from 842.76% in Q4 2025.
BioAge Labs (BIOA) EBITDA Margin (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed EBITDA Margin across 2 years of filings, most recently posting 810.17% for Q1 2026.
- EBITDA Margin for Q1 2026 came in at 810.17%, up 7949.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 873.6% (up 401682.0% YoY), and the FY2025 annual result was 895.74%, changed N/A from the prior year.
- EBITDA Margin came in at 810.17% for Q1 2026 at BioAge Labs, up from 842.76% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 810.17% in Q1 2026 to a low of 978.97% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | BioAge Labs | 671.19 Mn | 288.00 Mn | -10.37 Mn | -810.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -810.17% |
| Dec 31, 2025 | -842.76% |
| Sep 30, 2025 | -978.97% |
| Jun 30, 2025 | -896.14% |
| Mar 31, 2025 | -889.66% |